Peter Gelinas
Chief Technology Officer CoRegen
Seminars
Thursday 25th March 2027
Addressing Gene-Edited Treg Manufacturing Bottlenecks From Early Development Through to Clinical Readiness
1:00 pm
- Navigating donor-to-donor variability when developing manufacturing processes to improve consistency and support future scale-up initiatives
- Optimizing analytical strategies and characterization approaches to ensure the right assays are in place for evaluating gene-edited Treg products throughout development
- Balancing manufacturing scalability, product quality, and phenotypic functionality while preparing Treg therapies for successful clinical translation and broader commercialization